Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 3/20 | 0.56 |
| ▸ | LTB4R2 | Q9NPC1 | 4/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4161430 | 0.81 | MLYCD (0.68) | MLYCDALDH1A1HPGDSMN1; SMN2GLA | |
| SCHEMBL27654625 | 0.76 | ALDH1A1 (0.60) | LTB4R2KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL4153701 | 0.76 | MLYCD (0.59) | MLYCDLTB4R2ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL8791607 | 0.74 | ALDH1A1 (0.53) | MLYCDLTB4R2KDM4EALDH1A1HPGD | |
| SCHEMBL8699095 | 0.73 | MLYCD (0.64) | MLYCDNPY5RKDM4EFFAR1ALDH1A1 | |
| SCHEMBL4558654 | 0.73 | MLYCD (0.58) | MLYCDLTB4R2ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL26428573 | 0.72 | ROCK2 (0.52) | KDM4EALDH1A1MMP13TSHR | |
| SCHEMBL11958358 | 0.72 | KMT2A (0.51) | NPY5RKDM4EFFAR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL11262493 | 0.72 | ALDH1A1 (0.58) | LTB4R2KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL2202823 | 0.72 | KDM4E (0.62) | MLYCDNPY5RKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10660881-B2 | Compounds and compositions for inducing chondrogenesis | NOVARTIS AG (CH) | 2020-05-26 | — | — | US | disclosed |
| US-20190314348-A1 | COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. DBA THE GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190314348-A1 | COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS | FGF1, COL2A1, FGFR3 | MLYCD 3028/4885LTB4R2 1963/4885NPY5R 2079/4885 |
| US-10660881-B2 | Compounds and compositions for inducing chondrogenesis | FGF1, COL2A1, FGFR3 | MLYCD 3028/4885LTB4R2 1963/4885NPY5R 2079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.